Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 7684 results

  1. Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis [ID6480]

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

    In development [GID-TA11430] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour

    In development [GID-IPG10408] Expected publication date: 16 April 2025

    Interventional procedures guidance
    In development

  4. Bed frames for adults in acute settings

    In development [GID-HTE10050] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  5. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TSID 12043

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  8. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  9. Intermittent urethral catheters for urinary management in adults : Late Stage Assessment

    In development [GID-HTE10049] Expected publication date: TBC

    Health technology evaluations
    In development

  10. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development [GID-TA10981] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  11. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  12. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development [GID-TA11140] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  13. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development [GID-TA11554] Expected publication date: 12 November 2025

    Technology appraisal guidance
    In development

  14. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development